Ｖｅｒｉｔａｓ Ｉｎ Ｓｉｌｉｃｏの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2024/08/26 | 1,084 | 1,168 | 1,084 | 1,130 | +33 | +3% | 98,300 |
| 2024/08/23 | 1,158 | 1,170 | 1,078 | 1,097 | -91 | -7.7% | 179,100 |
| 2024/08/22 | 1,246 | 1,348 | 1,180 | 1,188 | +11 | +0.9% | 356,100 |
| 2024/08/21 | 1,130 | 1,210 | 1,072 | 1,177 | +47 | +4.2% | 251,100 |
| 2024/08/20 | 1,034 | 1,147 | 990 | 1,130 | +113 | +11.1% | 234,800 |
| 2024/08/19 | 988 | 1,060 | 969 | 1,017 | +48 | +5% | 188,800 |
| 2024/08/16 | 915 | 992 | 915 | 969 | +67 | +7.4% | 133,000 |
| 2024/08/15 | 880 | 913 | 860 | 902 | +23 | +2.6% | 62,500 |
| 2024/08/14 | 840 | 933 | 811 | 879 | +37 | +4.4% | 96,300 |
| 2024/08/13 | 850 | 880 | 785 | 842 | +112 | +15.3% | 185,600 |
| 2024/08/09 | 722 | 810 | 720 | 730 | +18 | +2.5% | 46,600 |
| 2024/08/08 | 688 | 726 | 680 | 712 | +25 | +3.6% | 30,500 |
| 2024/08/07 | 640 | 752 | 640 | 687 | +7 | +1% | 130,400 |
| 2024/08/06 | 638 | 716 | 638 | 680 | +43 | +6.8% | 116,700 |
| 2024/08/05 | 677 | 720 | 637 | 637 | -150 | -19.1% | 116,100 |
| 2024/08/02 | 838 | 838 | 774 | 787 | -96 | -10.9% | 110,000 |
| 2024/08/01 | 934 | 934 | 869 | 883 | -51 | -5.5% | 47,500 |
| 2024/07/31 | 934 | 946 | 871 | 934 | +13 | +1.4% | 66,900 |
| 2024/07/30 | 935 | 938 | 921 | 921 | -7 | -0.8% | 12,900 |
| 2024/07/29 | 933 | 943 | 920 | 928 | -4 | -0.4% | 14,800 |
| 2024/07/26 | 914 | 950 | 906 | 932 | +18 | +2% | 22,200 |
| 2024/07/25 | 918 | 926 | 901 | 914 | -7 | -0.8% | 39,800 |
| 2024/07/24 | 942 | 957 | 918 | 921 | -19 | -2% | 25,800 |
| 2024/07/23 | 933 | 946 | 917 | 940 | +7 | +0.8% | 43,200 |
| 2024/07/22 | 962 | 975 | 933 | 933 | -38 | -3.9% | 61,000 |
| 2024/07/19 | 975 | 992 | 963 | 971 | +1 | +0.1% | 40,500 |
| 2024/07/18 | 1,050 | 1,050 | 960 | 970 | -60 | -5.8% | 173,700 |
| 2024/07/17 | 998 | 1,063 | 993 | 1,030 | +36 | +3.6% | 100,500 |
| 2024/07/16 | 1,011 | 1,015 | 984 | 994 | -18 | -1.8% | 48,200 |
| 2024/07/12 | 982 | 1,032 | 981 | 1,012 | +12 | +1.2% | 50,600 |
| 2024/07/11 | 1,001 | 1,015 | 975 | 1,000 | ±0 | ±0% | 53,000 |
| 2024/07/10 | 1,007 | 1,024 | 991 | 1,000 | +16 | +1.6% | 54,700 |
| 2024/07/09 | 1,002 | 1,004 | 980 | 984 | -27 | -2.7% | 30,900 |
| 2024/07/08 | 1,020 | 1,032 | 954 | 1,011 | -9 | -0.9% | 113,500 |
| 2024/07/05 | 1,010 | 1,020 | 1,001 | 1,020 | +17 | +1.7% | 22,700 |
| 2024/07/04 | 1,012 | 1,055 | 1,002 | 1,003 | +1 | +0.1% | 71,700 |
| 2024/07/03 | 1,022 | 1,030 | 1,000 | 1,002 | -14 | -1.4% | 60,900 |
| 2024/07/02 | 1,051 | 1,053 | 1,005 | 1,016 | -35 | -3.3% | 81,800 |
| 2024/07/01 | 1,090 | 1,090 | 1,020 | 1,051 | -47 | -4.3% | 100,000 |
| 2024/06/28 | 1,210 | 1,210 | 1,088 | 1,098 | -102 | -8.5% | 159,200 |
| 2024/06/27 | 1,161 | 1,223 | 1,147 | 1,200 | +43 | +3.7% | 85,900 |
| 2024/06/26 | 1,185 | 1,215 | 1,150 | 1,157 | -15 | -1.3% | 59,200 |
| 2024/06/25 | 1,155 | 1,200 | 1,137 | 1,172 | +20 | +1.7% | 31,600 |
| 2024/06/24 | 1,187 | 1,198 | 1,152 | 1,152 | -16 | -1.4% | 38,100 |
| 2024/06/21 | 1,080 | 1,225 | 1,080 | 1,168 | +88 | +8.1% | 122,000 |
| 2024/06/20 | 1,178 | 1,236 | 1,072 | 1,080 | -40 | -3.6% | 115,100 |
| 2024/06/19 | 1,125 | 1,125 | 1,099 | 1,120 | +1 | +0.1% | 14,000 |
| 2024/06/18 | 1,140 | 1,140 | 1,103 | 1,119 | -22 | -1.9% | 11,100 |
| 2024/06/17 | 1,113 | 1,141 | 1,096 | 1,141 | +28 | +2.5% | 5,000 |
| 2024/06/14 | 1,138 | 1,150 | 1,098 | 1,113 | -55 | -4.7% | 22,100 |
151～
200
件表示中 / 285件
類似銘柄と比較する
現在ご覧いただいている「ＶＩＳ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| ＶＩＳ | 61,500円 | +306.2% | - | 0.00% | 23.75倍 | 1.81倍 |
|
ｍＲＮＡ標的低分子創薬技術を製薬会社に提供。共同創薬研究などによる契約金収入が柱 |
| ＤＷＴＩ | 10,000円 | -15.1% | - | 0.00% | - | 6.18倍 |
|
三重大学発創薬ベンチャー。プロテインキナーゼ阻害剤開発技術はじめ眼病治療薬開発に集中 |
| ＤＥＬＴＡ－Ｐ | 46,200円 | - | - | 0.00% | - | 14.32倍 |
|
創薬ベンチャー。既存の抗がん物質を組み合わせて安全性と有効性を高めた抗がん剤を開発 |
| 免疫生物 | 41,200円 | +13.4% | +44.0% | 0.00% | 17.85倍 | 2.87倍 |
|
研究用試薬の製販・受託。遺伝子組み換えカイコの基礎研究は休止し、化粧品等応用開発に移行 |
| リボミック | 8,100円 | - | - | 0.00% | - | 1.10倍 |
|
東大発の創薬ベンチャー。ＲＮＡ（リボ核酸）を利用した分子標的薬（アプタマー医薬）を開発 |
市場注目の銘柄
チャート関連のコラム
